Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
IDH1 mutant Dasatinib chondrosarcoma resistant detail...
Unknown unknown Alisertib chondrosarcoma not applicable detail...
Unknown unknown Dasatinib chondrosarcoma not applicable detail...
Unknown unknown Pembrolizumab chondrosarcoma not applicable detail...
Unknown unknown Doxorubicin + Nilotinib chondrosarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01446809 Phase I Doxorubicin + Ifosfamide Pazopanib + Doxorubicin + Ifosfamide Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Unknown status
NCT03190174 Phase Ib/II Nab-Rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting
NCT03282344 Phase II NKTR-214 + Nivolumab A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting
NCT03684811 Phase Ib/II Cisplatin + FT-2102 + Gemcitabine FT-2102 + Azacitidine FT-2102 FT-2102 + Nivolumab A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Recruiting